350 related articles for article (PubMed ID: 15127320)
41. Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus.
Davì G; Belvedere M; Vigneri S; Catalano I; Giammarresi C; Roccaforte S; Consoli A; Mezzetti A
Thromb Haemost; 1996 Jul; 76(1):34-7. PubMed ID: 8819248
[TBL] [Abstract][Full Text] [Related]
42. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
Hamsten A; Syvänne M; Silveira A; Luong LA; Nieminen MS; Humphries S; Frick MH; Taskinen MR
Thromb Haemost; 2000 Mar; 83(3):397-403. PubMed ID: 10744143
[TBL] [Abstract][Full Text] [Related]
43. Different mechanisms of fibrinolysis impairment among dyslipidemic subjects.
Puccetti L; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Auteri A; Bruni F
Int J Clin Pharmacol Res; 2001; 21(3-4):147-55. PubMed ID: 12067144
[TBL] [Abstract][Full Text] [Related]
44. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
45. Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.
Mansfield MW; Catto AJ; Carter AM; Grant PJ
Diabet Med; 1998 Nov; 15(11):953-7. PubMed ID: 9827850
[TBL] [Abstract][Full Text] [Related]
46. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
Lester JW; Fernandes AW
Int J Clin Pract; 2005 Feb; 59(2):134-42. PubMed ID: 15854187
[TBL] [Abstract][Full Text] [Related]
47. The effects of insulin-like growth factor-1 on plasminogen activator inhibitor-1 synthesis and secretion: results from in vitro and in vivo studies.
Padayatty SJ; Orme S; Zenobi PD; Stickland MH; Belchetz PE; Grant PJ
Thromb Haemost; 1993 Dec; 70(6):1009-13. PubMed ID: 8165592
[TBL] [Abstract][Full Text] [Related]
48. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
49. Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis.
Kamper EF; Kopeikina LT; Koutsoukos V; Stavridis J
J Rheumatol; 1997 Feb; 24(2):262-8. PubMed ID: 9034981
[TBL] [Abstract][Full Text] [Related]
50. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Aso Y; Wakabayashi S; Yamamoto R; Matsutomo R; Takebayashi K; Inukai T
Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
[TBL] [Abstract][Full Text] [Related]
51. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes.
Skrha J; Stulc T; Hilgertová J; Weiserová H; Kvasnicka J; Ceska R
Eur J Pharmacol; 2004 Jun; 493(1-3):183-9. PubMed ID: 15189781
[TBL] [Abstract][Full Text] [Related]
52. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
[TBL] [Abstract][Full Text] [Related]
53. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy.
Brazionis L; Rowley K; Jenkins A; Itsiopoulos C; O'Dea K
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):786-91. PubMed ID: 18239151
[TBL] [Abstract][Full Text] [Related]
54. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
[TBL] [Abstract][Full Text] [Related]
55. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
Rigla M; Wägner AM; Borrell M; Mateo J; Foncuberta J; de Leiva A; Ordóñez-Llanos J; Pérez A
Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
[TBL] [Abstract][Full Text] [Related]
56. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
Davidson JA; Perez A; Zhang J;
Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
[TBL] [Abstract][Full Text] [Related]
57. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
[TBL] [Abstract][Full Text] [Related]
58. Systemic coagulation and fibrinolysis in patients with or at risk for the adult respiratory distress syndrome.
Groeneveld AB; Kindt I; Raijmakers PG; Hack CE; Thijs LG
Thromb Haemost; 1997 Dec; 78(6):1444-9. PubMed ID: 9423792
[TBL] [Abstract][Full Text] [Related]
59. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Fogari R; Derosa G; Lazzari P; Zoppi A; Fogari E; Rinaldi A; Mugellini A
Am J Hypertens; 2004 Sep; 17(9):823-7. PubMed ID: 15363826
[TBL] [Abstract][Full Text] [Related]
60. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes.
Panahloo A; Mohamed-Ali V; Andrés C; Denver AE; Yudkin JS
Metabolism; 1998 Jun; 47(6):637-43. PubMed ID: 9627359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
